An observational study in Sepsis, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-08.
Sponsored by Ain Shams University · Observational
Presepsin (soluble CD14 subtype) is a novel marker with growing body of evidence supporting its accuracy and value for the diagnosis of sepsis. Patients with sepsis showed higher Prsepsin levels compared to those with SIRS. In addition the increase in Prsepsin levels correlates well with sepsis severity. Red cell distribution width variations are increased in a variety of medical conditions such as congestive heart failure, acute myocardial infarction, pulmonary embolism, pneumonia, critical illness, and cardiac arrest , and is a predictor of mortality in the general population. we aim to compare between Presepsin (soluble CD14) and RDW as prognostic markers in critically-ill patients with sepsis.
1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.
This study's enrollment of 200 is above the median of 160 across 931 observational studies indexed under Sepsis.
Browse Sepsis studies →Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients admitted to the general ICU with sepsis or septic shock of both sexes between 18 and 65 years of age.
Exclusion Criteria:
RDW was assessed as part of complete blood count analysis using SYSMEX XN-550 automated analyzer
Diagnostic Test: Red Cell Distribution Width (RDW)
Presepsin analysis was done by utilising Elisa technique using kits from (MyBioSource, San Diego, CA 92195-3308 USA)
Diagnostic Test: Presepsin (sCD14-ST)
A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.
: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
Mortality during intensive care unit stay
Time frame: 28 days
Length of ICU stay
Time frame: assessed up to 3 months
Need for readmission to ICU
Time frame: assessed up to 3 months
Ventilatory support duration
Time frame: assessed up to 3 months
Number of participants who need renal replacement therapy
Time frame: assessed up to 3 months
Number of participants who need inotropic or vasopressor support
Time frame: assessed up to 3 months
Transfusion requirements (blood and blood products)
Time frame: assessed up to 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ain Shams University